Navigation Links
New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus

Data Presented at Leading Influenza Conference

HIGH WYCOMBE, UK 18th June 2007-Previously undisclosed pre-clinical data showing how a new flu vaccine has the potential to protect against all strains of influenza, including pandemic and annual, was presented today by PepTcell, at the 2007 Options for the Control of Influenza VI (Options) Conference, in Toronto, Canada.

The pre-clinical results, which will be published in the European Journal of Immunology, showed how mice vaccinated with PepTcell's novel flu vaccine, FLU-v, had a significantly increased survival rate when challenged with a lethal dose of influenza virus, compared with those that received a control vaccine.

Dr Wilson Caparros-Wanderley, PepTcell's Chief Scientific Officer said: "These are extremely encouraging results for PepTcell's FLU-v vaccine. They show that a vaccine, targeted at parts of the virus which do not change from year-to-year, can be effective against lethal influenza strains."

The data showed how PepTcell has used a novel proprietary prediction algorithm to locate conserved immunogenic regions in animal and human strains of flu virus. The analysis identified six highly conserved regions within several proteins that are capable of triggering an immune response.

These six regions were then chemically synthesised as small protein fragments called peptides. The resulting preparation, FLU-v, was used to immunise eight transgenic mice. At the same time a group of eight control mice were immunised with a set of non-related peptides.

Following immunisation with FLU-v the mice launched a specific T-cell immune response of the CD8+ subtype against the peptides. T-cells are part of the immune system, helping to fight off infection and disease by killing abnormal cells. The CD8+ T-cells isolated from the mice showed activity against human cells infected with three unrelated influenza strains in in vit
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
3. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
6. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
9. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
10. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:5/16/2008)...gy Enables First-Ever PEGylation of a Small Molecu... Activity, SAN CARLOS, Calif., May 16 /PRNewswire...) announced initial results today from a Phase 1,s...shows significant,anti-tumor activity in patients ...strates that Nektar,s small molecule PEGylation te...
(Date:5/15/2008)...onfirm Efficacy for Population Most Affected by Di...16 /-,Bayer HealthCare Phar...Nasdaq: ONXX ) today announced that Nexavar(R) (s...urvival by 47.3 percent (HR=0.68;,p-value=0.014) i...d,hepatocellular carcinoma (HCC), or primary liver...
(Date:5/15/2008)...cacy Clinical Data from Prostate, Colorectal and O... Company to Hold Investor Event on Sun., June 1 wi...., May 15 /- Poniard,Pharma...cal company focused,on oncology, today announced t...cal trials of picoplatin, in various tumor types a...
(Date:5/15/2008)...uctions demonstrated in Blacks, Hispanics/Latinos,...ndividuals, PARSIPPANY, N.J., May 15 /PRNewswire/...a presented at the American Society of,Hypertensio...008) in New,Orleans demonstrated that the powerful...tan medoxomil) safely and effectively helped,patie...
Breaking Medicine Technology:Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Finola Hughes Announces Her Best Accessory at Fashion Week 10829 1Finola Hughes Announces Her Best Accessory at Fashion Week 10829 2Finola Hughes Announces Her Best Accessory at Fashion Week 10829 3Natural Nutrition Operating Subsidiary Reports Record 29 25 Increase in Revenues for 2007 of 2417 460 000 10827 1Natural Nutrition Operating Subsidiary Reports Record 29 25 Increase in Revenues for 2007 of 2417 460 000 10827 2Diagnostic Centers of America Retains NewsMark Public Relations to Showcase Its Rise as Only Medical Facility in South Florida With Worlds Most Advanc 10823 1Diagnostic Centers of America Retains NewsMark Public Relations to Showcase Its Rise as Only Medical Facility in South Florida With Worlds Most Advanc 10823 2Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland 2951 1Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland 2951 2
...Impact of Pain on Sleep Interference, INDIANAPOLIS... a,pooled analysis of three studies suggest that i...ge, or diabetic peripheral neuropathy,who are tre...in,both average daily pain and night pain severity...rference than in those patients,taking sugar pill....
...SX Venture Exchange, EDMONTON, May 02, 2007 /PRNew...or the "Company") Quest is pleased to provide an,u... the treatment,of prostate cancer. , Prostate canc...American men with approximately 230,000 new cases ...dalities for localized prostate,cancer are associa...
Other Medicine Technology:Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 2Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 3Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 4Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 5Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 6Quest PharmaTech's Prostate Cancer Program Update 2Quest PharmaTech's Prostate Cancer Program Update 3
(Date:5/17/2008)...ed Spokesperson for Education Campaign on Behalf o...teinase Inhibitor (Human) Augmentation ..., May 17 /PRNewswire/ -- Melissa Biggs, a fashion,...recently named,spokesperson for an education campa...ans to get tested for alpha-1 antitrypsin (AAT) de...
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
(Date:5/16/2008)...g Campaign to Emphasize the Importance of Oral and...ire/ -- National dental insurer United,Concordia D...boration,between Oral Health America and the Briti...nce of oral health to overall health. Beginning Ma... States for the first time,making it the largest ...
(Date:5/16/2008)...s chronic disease sufferers gain benefit from calc...(HealthDay News) -- Taking activated vitamin D may... severe chronic kidney disease by about one quarte...tudy of more than 1,400 patients, those being trea...amin D, had their overall risk of death lowered by...
Breaking Medicine News(10 mins):Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 2Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 3Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 4Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 5Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2
...eat America dream-this may be the epitome of man...his fast life at neck-break speed,// takes its p...t close to one- fourth of all hospital stays in th...arious psychological disorders as well as substanc...
...mber of male babies born in the U.S. is dropping. ... in the changing demographic pattern//, says a new...h is on a steady decline for the last three decade...fewer white males in the last 30 years in the U.S....
...ia gears up to implement the third phase of its Na...ll districts will be made implementing// authoriti...d. The goal is to "to halt and reverse the epidem...billion ($2 billion), according to a draft executi...
...ge is good for you and knowing how to make your a ...have the knowledge and skill// which can be learne...e education is what the Marriage Resource Center o...ryday. Here is an opportunity for couples who are ...
Other Medicine News:Health News:‘Land Of Dreams’ Staggers Under The Weight Of Neuroses And Substance Abu 2Health News:‘Land Of Dreams’ Staggers Under The Weight Of Neuroses And Substance Abu 3Health News:Male Child Birth Dropping in US and Japan 2Health News:India to Hike Free Treatments in Fight Against AIDS 2
...S solution tricompartmental total knee prosthesis ...roplasty. State-of-the-art design and manufacturin...optimum biomechanical function as well as a favora...ene tibial insert to keep wear to a minimum. The i...
...knee system was designed for patients with difficu...ons needed custom designs to repair difficult anat... Factor' which reduces the chance of dislocation i...tation has been streamlined and updated so that th...
The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively.
...S Solution tricompartmental total knee prosthesis ...roplasty. State-of-the-art design and manufacturin...optimum biomechanical function as well as a favora...ene tibial insert to keep wear to a minimum. The i...
Medicine Products: